Provided by Tiger Trade Technology Pte. Ltd.

Adicet Bio, Inc.

6.47
-0.2600-3.86%
Post-market: 6.45-0.0206-0.32%18:36 EDT
Volume:105.08K
Turnover:686.73K
Market Cap:61.97M
PE:-0.38
High:6.66
Open:6.62
Low:6.42
Close:6.73
52wk High:17.44
52wk Low:6.41
Shares:9.58M
Float Shares:8.25M
Volume Ratio:1.11
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.9500
EPS(LYR):-16.9493
ROE:-67.55%
ROA:-37.00%
PB:0.39
PE(LYR):-0.38

Loading ...

Adicet Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 07, 2025

Adicet Bio Q3 EPS $(0.29) Beats $(0.30) Estimate

Benzinga
·
Nov 06, 2025

Adicet Bio Reports Positive Preliminary Phase 1 Data and Extends Cash Runway Into 2027

Reuters
·
Nov 06, 2025

Gene therapy firm MaxCyte misses Q3 revenue estimates

Reuters
·
Nov 05, 2025

BRIEF-Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 01, 2025

Adicet Bio Grants Stock Options to New Hires Under Inducement Plan

Reuters
·
Nov 01, 2025

Adicet Bio Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

Canaccord Genuity Remains a Buy on Adicet Bio (ACET)

TIPRANKS
·
Oct 17, 2025

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Adi-001 in Treatment-Refractory Rheumatoid Arthritis (Ra)

THOMSON REUTERS
·
Oct 16, 2025

Adicet Bio Inc - Preliminary Data From Phase 1 Trial Expected in 2H/2026

THOMSON REUTERS
·
Oct 16, 2025

Adicet Bio Is Maintained at Buy by Guggenheim

Dow Jones
·
Oct 08, 2025

Guggenheim Sticks to Their Buy Rating for Adicet Bio (ACET)

TIPRANKS
·
Oct 08, 2025

Adicet Bio Receives Nasdaq Extension to Regain Compliance After Failing Minimum Bid Price Requirement

Reuters
·
Oct 08, 2025

Adicet Bio Announces $80 Million Registered Direct Offering of Common Stock and Pre-Funded Warrants

Reuters
·
Oct 07, 2025

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Announces Positive Phase 1 Results for ADI-001 in Lupus Nephritis and SLE, Plans Pivotal Phase 2 Trial in 2026

Reuters
·
Oct 07, 2025

Adicet Bio Inc - Adi-001 Well Tolerated With No Icans Observed

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Announces Positive Preliminary Data From Adi-001 Phase 1 Study in Patients With Lupus Nephritis (Ln) and Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Inc - Plans FDA Meeting in 1Q/2026 for Phase 2 Trial

THOMSON REUTERS
·
Oct 07, 2025

Adicet Bio Inc - as of Aug 31, All Patients Show Reductions in Sledai-2K Score

THOMSON REUTERS
·
Oct 07, 2025